An Open-label, Single-arm, Pilot Study to Evaluate the Effect of XmAb5871 on Disease Activity in Patients With IgG4-Related Disease.

Trial Profile

An Open-label, Single-arm, Pilot Study to Evaluate the Effect of XmAb5871 on Disease Activity in Patients With IgG4-Related Disease.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs XmAb 5871 (Primary)
  • Indications Immunological disorders
  • Focus Therapeutic Use
  • Sponsors Xencor
  • Most Recent Events

    • 29 Jun 2017 Planned End Date changed from 1 Apr 2018 to 1 Mar 2018.
    • 17 Jun 2017 Fifteen patients were enrolled between March 2016 and January 2017 as reported by results presented at the 18th Annual Congress of the European League Against Rheumatism
    • 17 Jun 2017 Interim results (n=12 data cut off: 31 Oct 2016) presented at the 18th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top